Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
COMTAN | Orion Pharma | N-020796 RX | 1999-10-19 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
STALEVO 50 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD, RS |
STALEVO 100 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
STALEVO 150 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
STALEVO 200 | Orion Pharma | N-021485 RX | 2007-08-02 | 1 products, RLD, RS |
STALEVO 75 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
STALEVO 125 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
carbidopa, levodopa and entacapone | ANDA | 2022-02-01 |
carbidopa, levodopa, and entacapone | NDA authorized generic | 2016-02-01 |
comtan | New Drug Application | 2021-07-30 |
entacapone | ANDA | 2024-10-23 |
stalevo | New Drug Application | 2021-07-30 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
parkinson disease | EFO_0002508 | D010300 | G20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | 12 | 12 | 6 | 12 | 6 | 46 |
Treatment adherence and compliance | D000074822 | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cocaine-related disorders | D019970 | — | F14 | 1 | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Nervous system diseases | D009422 | — | G00-G99 | 1 | 3 | — | — | 1 | 4 |
Shy-drager syndrome | D012791 | EFO_1001050 | — | 2 | 1 | — | — | 1 | 3 |
Multiple system atrophy | D019578 | — | — | 2 | 1 | — | — | 1 | 3 |
Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 2 | — | — | — | 2 |
Brain diseases | D001927 | HP_0001298 | G93.40 | — | 2 | — | — | — | 2 |
Movement disorders | D009069 | HP_0100022 | — | — | 2 | — | — | — | 2 |
Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | — | — | — | 2 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | 1 | 2 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | — | — | 1 |
Body weight | D001835 | EFO_0004338 | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
Lewy body disease | D020961 | EFO_0006792 | G31.83 | 1 | — | — | — | — | 1 |
Dementia | D003704 | EFO_0003862 | F03 | 1 | — | — | — | — | 1 |
Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | — | — | — | 1 | 1 |
Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | — | — | — | — | 1 | 1 |
Huntington disease | D006816 | Orphanet_399 | G10 | — | — | — | — | 1 | 1 |
Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
Corticobasal degeneration | D000088282 | — | — | — | — | — | — | 1 | 1 |
Narcolepsy | D009290 | HP_0030050 | G47.4 | — | — | — | — | 1 | 1 |
Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
Parasomnias | D020447 | — | G47.5 | — | — | — | — | 1 | 1 |
Drug common name | Entacapone |
INN | entacapone |
Description | Entacapone is a monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor, an antiparkinson drug, a central nervous system drug and an antidyskinesia agent. It is a monocarboxylic acid amide, a nitrile, a member of catechols and a member of 2-nitrophenols. |
Classification | Small molecule |
Drug class | catechol-O-methyltransferase (COMT) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1 |
PDB | — |
CAS-ID | 130929-57-6 |
RxCUI | — |
ChEMBL ID | CHEMBL953 |
ChEBI ID | 4798 |
PubChem CID | 5281081 |
DrugBank | DB00494 |
UNII ID | 4975G9NM6T (ChemIDplus, GSRS) |